证券代码：688575 证券简称：亚辉龙 公告编号：2023-043 深圳市亚辉龙生物科技股份有限公司 关于自愿披露取得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳市亚辉龙生物科技股份有限公司（以下简称"公司"或"亚辉龙"）于近日收 到了由广东省药品监督管理局签发的医疗器械注册证,具体信息如下: 序 号 产品名称 注册编号 注册证有效期 注册 分类 预期用途 1 高敏肌钙蛋白 I 测定 试剂盒（化学发光法） 粤械注准 20232401482 至 2028/9/5 二类 用于体外定量测定人血清和（或）血 浆中心肌肌钙蛋白 I（cTnI）的含量， 临床上主要用于心肌梗死的辅助诊 断。 特此公告。 深圳市亚辉龙生物科技股份有限公司 一、医疗器械注册证的基本情况 二、对公司的影响 随着肌钙蛋白检测敏感性的不断提高，高敏心肌肌钙蛋白 I（hs-cTnI）的检测在 临床实验室的广泛开展。与传统肌钙蛋白检测相比，hs-cTnI 有助于探查既往易被漏诊 的微小心肌损伤、更早期诊断 AMI、更合理筛查心血管事件 ...

中信证券股份有限公司 二、保荐机构和保荐代表人发现的问题及整改情况 无。 关于深圳市亚辉龙生物科技股份有限公司 2023 年半年度持续督导跟踪报告 中信证券股份有限公司（以下简称"中信证券"、"保荐机构"）为深圳市亚辉 龙生物科技股份有限公司（以下简称"公司"、"亚辉龙"）首次公开发行股票并上 市的保荐机构。根据《证券发行上市保荐业务管理办法》、《上海证券交易所科 创板股票上市规则（2020 年 12 月修订）》等相关规定，负责亚辉龙上市后的持 续督导工作，并出具本持续督导半年度跟踪报告。 | 一、持续督导工作情况 | | --- | | 序号 | 工作内容 | 实施情况 | | --- | --- | --- | | 1 | 建立健全并有效执行持续督导工作制度，并针 对具体的持续督导工作制定相应的工作计划。 | 保荐机构已建立健全并有效执行了持 续督导制度，并制定了相应的工作计 | | | | 划。 | | | 根据中国证监会相关规定，在持续督导工作开 始前，与上市公司签署持续督导协议，明确双 | 保荐机构已与亚辉龙签订保荐协议，该 协议明确了双方在持续督导期间的权 | | 2 | 方在持续督导期间的权利义 ...

Financial Performance - The company's operating revenue for the first half of 2023 was approximately ¥1.075 billion, a decrease of 54.00% compared to ¥2.337 billion in the same period last year[22]. - The net profit attributable to shareholders of the listed company was approximately ¥141.53 million, down 78.74% from ¥665.72 million year-on-year[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥128.18 million, a decrease of 78.98% compared to ¥609.83 million in the previous year[22]. - The net cash flow from operating activities was negative at approximately -¥545.49 million, compared to a positive cash flow of ¥618.48 million in the same period last year, representing a decline of 188.20%[22]. - The net assets attributable to shareholders of the listed company at the end of the reporting period were approximately ¥2.324 billion, a decrease of 3.81% from ¥2.417 billion at the end of the previous year[22]. - Total assets at the end of the reporting period were approximately ¥3.583 billion, down 14.93% from ¥4.212 billion at the end of the previous year[22]. - Basic earnings per share decreased by 78.63% to CNY 0.25 compared to CNY 1.17 in the same period last year[24]. - Diluted earnings per share also decreased by 78.63% to CNY 0.25 from CNY 1.17 year-over-year[24]. - The weighted average return on equity dropped by 30.6 percentage points to 5.68% from 36.28% in the previous year[24]. Research and Development - The R&D investment as a percentage of operating revenue increased by 7.61 percentage points to 13.29% from 5.68% year-over-year[24]. - The company invested a total of 14,285.65 thousand yuan in R&D during the reporting period, with a cumulative investment of 67,745.11 thousand yuan[139]. - The number of R&D personnel increased to 609, representing 30.28% of the total workforce, up from 456 and 29.06% respectively in the same period last year[5]. - Total compensation for R&D personnel was 7,213.01 million, slightly up from 7,084.60 million year-on-year[5]. - Average salary for R&D personnel decreased to 12.24 million from 16.81 million in the previous year[5]. - The company has a total of 602 intellectual property applications, with 287 granted[121]. - The company has a strong focus on R&D, with a well-established structure and rich experience, ensuring continuous innovation and competitiveness in the market[168]. Market Position and Strategy - The company aims to compete comprehensively in the clinical diagnostics product line against major players like Roche, Abbott, and Siemens[41]. - The company is committed to becoming a global leader in the in vitro diagnostics industry, focusing on three core areas: coagulation, emergency diagnostics, and autoimmunity[41]. - The core product of the company is chemiluminescence instruments and related reagents, which dominate over 70% of the immunodiagnosis market in China[56]. - The company is positioned in a technology-intensive industry, with significant potential for domestic product development and market share growth in high-tech areas like chemiluminescence[66]. - The company aims to benefit from the increasing demand for immunodiagnostic products driven by the hierarchical medical system reform in China[60]. - The company has a strong market presence, with sales experience spanning over a decade and a marketing network covering over 100 countries and regions globally[111]. Product Development and Innovation - The company has established a comprehensive in vitro diagnostic technology platform, successfully developing a magnetic microparticle chemiluminescence platform, and has become one of the early adopters in China for the industrialization of related products[101]. - As of June 30, 2023, the company has obtained registration certificates for 153 chemiluminescence diagnostic projects, covering routine detection items and specialized testing projects[101]. - The company launched 5 new testing reagent projects, including 3 chemiluminescence detection projects, which received domestic and international registration certificates[183]. - The company has developed and registered 3 new chemiluminescence immunoassay diagnostic projects during the reporting period[136]. - The company’s automated chemiluminescence immunoassay analyzers can achieve testing speeds of up to 2,400 tests per hour when connected in modules, enhancing operational efficiency[104]. Challenges and Risks - The company faces risks related to the US-China trade friction, which could adversely affect its operations[195]. - There are risks associated with new product registrations that could impact the company's market position[196]. - Regulatory changes in the medical industry, including quality control and procurement processes, may pose challenges if the company fails to adapt its strategies accordingly[198]. - The company anticipates that reforms in the healthcare system, such as the "two-invoice system" and centralized procurement, will gradually be implemented, affecting its operational strategies[198]. - Failure to optimize the distribution system and maintain R&D investment could lead to a decline in operational performance[198]. - The company must align its strategies with ongoing healthcare reforms to mitigate risks of performance decline[198].

证券代码：688575 证券简称：亚辉龙 公告编号：2023-040 深圳市亚辉龙生物科技股份有限公司 第三届监事会第十四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳市亚辉龙生物科技股份有限公司（以下简称"公司"）第三届监事会第十四次 会议（以下简称"本次会议"）于 2023 年 8 月 16 日以现场加通讯方式召开，会议应到 监事 3 人，实到监事 3 人，出席监事占应出席人数的 100%。本次会议的召集、召开 程序符合《公司章程》和有关法律、法规的要求。经与会监事审议和表决，会议形成 如下决议： 一、审议通过《关于公司<2023 年半年度报告>及其摘要的议案》 公司编制和审核《2023 年半年度报告》及其摘要的程序符合法律、行政法规和 中国证监会的规定，报告内容真实、准确、完整地反映了公司的实际情况，不存在任 何虚假记载、误导性陈述或者重大遗漏。 具体内容详见同日在上海证券交易所网站（www.sse.com.cn）上披露的《2023 年 半年度报告》及《2023 年半年度报告摘要》。 表决结果： ...

证券代码：688575 证券简称：亚辉龙 公告编号：2023-041 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 (一)实际募集资金金额及资金到账时间 根据中国证券监督管理委员会于2021年3月9日核发的《关于同意深圳市亚辉龙 生物科技股份有限公司首次公开发行股票注册的批复》（证监许可[2021]755号）， 公司向社会公众公开发行人民币普通股（A股）4,100万股（每股面值人民币1元）， 并于2021年5月17日在上海证券交易所科创板上市（以下简称"本次发行"）。本 次发行的发行价格为14.80元/股，本次发行募集资金总额606,800,000.00元，扣除 公司不含增值税的保荐及承销费以及其他发行费用后募集资金净额为 541,334,440.75元。大华会计师事务所（特殊普通合伙）已于2021年5月12日出具 大华验字[2021]000303号《验资报告》，验证募集资金已全部到位。公司已对募集 资金进行了专户存储，并与保荐机构、存放募集资金的商业银行签署了相关监管协 议。 (二)募集资金使用与结余情况 本公司202 ...

证券代码：688575 证券简称：亚辉龙 公告编号：2023-042 深圳市亚辉龙生物科技股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 为提高交流效率，公司现提前向投资者征集相关问题，欢迎广大投资者于 2023 年 08 月 22 日(星期二)至 08 月 28 日(星期一)16:00 前登录上证路演中心网 站首页点击"提问预征集"栏目或通过公司投资者关系邮箱 ir@szyhlo.com 进行 提问。公司将在说明会上对投资者普遍关注的问题进行回答。 深圳市亚辉龙生物科技股份有限公司（以下简称"公司"）已于 2023 年 8 月 18 日发布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年半年度经营成果、财务状况，公司计划于 2023 年 08 月 29 日下午 16:00-17:00 举行 2023 年半年度业绩说明会，就 ...

深圳市亚辉龙生物科技股份有限公司 独立董事关于第三届董事会第十五次会议相关事项的 独立意见 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》(以下简称"《证券法》")、《上海证券交易所科创板股票 上市规则》(以下简称"《上市规则》"）、《上海证券交易所科创板上市公司 自律监管指引第1 号 -- 规范运作》（以下简称"《规范运作》"）、《上市公 司独立董事规则》等法律法规及、《深圳市亚辉龙生物科技股份有限公司章程》 (以下简称"《公司章程》")的相关规定,作为深圳市亚辉龙生物科技股份有 限公司(以下简称"公司")的独立董事,我们在认真审查相关文件资料后,现 就公司第三届董事会第十五次会议的相关事项，发表独立意见如下: 一、《关于公司<2023 年半年度募集资金存放与实际使用情况专项报告>的 议案》 公司已按《上市公司监管指引第2号 -- 上市公司募集资金管理和使用的监 管要求(2022年修订)》、《规范运作》相关规定及时、真实、准确、完整地 披露了公司募集资金的存放及实际使用情况,不存在募集资金管理违规的情况。 公司对募集资金的投向和进展情况均如实履行了披露义务。 综上,我们同 ...

Financial Performance - The company achieved a net cash flow from operating activities of approximately ¥1,583.16 million, a significant increase of 509.80% compared to ¥259.62 million in the previous year, primarily due to expanded sales scale and increased sales collections [35]. - The company's revenue for the current period reached 182,133.18 million RMB, a significant increase of 275.62% compared to the previous year [54]. - The overseas non-COVID self-operated business revenue was 10,988.50 million RMB, reflecting a year-on-year growth of 19.66% [50]. - The company reported a total revenue of 24,101.49 million with a net profit of 573.81 million, indicating a strong performance in the in vitro diagnostic product agency business [96]. - The company’s overseas operations, represented by Hong Kong Yahui Long, generated a revenue of 11,523.45 million with a net profit of 5,156.34 million, showcasing successful international expansion [96]. Investment and R&D - The company invested approximately ¥106.65 million during the reporting period, a substantial increase of 198.86% compared to ¥35.68 million in the previous year [40]. - The company has a well-structured R&D team, with 227 master's degree holders and 17 doctoral degree holders, contributing to its innovation capabilities [3]. - The company has made significant investments in new technologies and products, including the acquisition of Biointelligence and the development of new in vitro diagnostic products [68]. - The company has established a strong technical barrier in the field of autoimmune disease diagnosis, leveraging over a decade of experience and a mature R&D platform [69]. - The company is actively developing new diagnostic projects to expand its market share and enhance its competitive edge [99]. Inventory and Asset Management - The company reported a total inventory value of ¥569.54 million, accounting for 22.83% of total current assets, indicating potential risks related to inventory turnover and asset quality [16]. - The inventory level increased to 569,535,592.27 RMB, representing 13.52% of total assets, due to expanded business operations and increased raw material stock [61]. - The company has a total asset value of 23,225.10 million and a net asset value of 8,775.79 million, reflecting a solid financial position [96]. Profit Distribution and Dividends - The company has a profit distribution policy prioritizing cash dividends, with a minimum of 10% of distributable profits allocated annually in cash when conditions are met [93]. - The company plans to distribute a cash dividend of RMB 4.5 per 10 shares, totaling RMB 255,150,000, which represents 25.20% of the net profit attributable to shareholders [152]. - The average annual cash dividend over the past two years has exceeded 30% of the average net profit attributable to shareholders [150]. - The company can implement stock dividends alongside cash dividends while ensuring sufficient cash dividend distribution [126]. - The company plans to conduct at least one profit distribution annually, with distributions occurring within two months after approval at the annual shareholders' meeting [122]. Employee and Talent Management - The total number of employees in the parent company is 1,268, with 569 employees in major subsidiaries, resulting in a total of 1,837 employees [119]. - The company emphasizes talent development through training programs and a joint cultivation plan for advanced degrees, aiming to build a sustainable talent pipeline [90]. - The company has a total of 1,837 employees, including 570 R&D personnel and 432 technical staff [141]. - The company regularly conducts employee training and development programs to enhance workforce skills and career growth opportunities [170]. Corporate Governance and Compliance - The company completed 4 periodic reports and 95 temporary announcements in 2022, ensuring compliance with information disclosure regulations [72]. - The company has maintained a standard unqualified audit opinion on its financial reports for the year [145]. - The company has established a comprehensive internal control system to manage subsidiaries and mitigate operational risks [160]. - The company emphasizes investor relations management and protection, conducting various communication activities to improve investor understanding and company transparency [199]. Social Responsibility and Sustainability - The company has actively engaged in social responsibility initiatives, donating a total of RMB 1,058.91 million, including RMB 100 million in cash donations [167]. - The company has established an environmental protection mechanism, investing 628,000 CNY in environmental protection during the reporting period [180]. - The company donated nearly 4 million COVID-19 antigen test kits and protective equipment to various regions, emphasizing its commitment to social responsibility [189]. - The company has committed to sustainable development practices, integrating ESG considerations into its daily operations [160]. Market Expansion and Strategy - The company plans to continue its market expansion efforts, focusing on increasing its presence in overseas markets and enhancing its product offerings [68]. - The company plans to enhance its product offerings in the autoimmune disease sector, aiming to become a benchmark brand in domestic diagnostics while contributing to public health [69]. - The company is positioned as a leader in the reproductive diagnostic sector, aiming to develop this area alongside its existing immunodiagnostic offerings [99].

2023 年第一季度报告 8 / 14 | --- | --- | --- | |-------------------------------|------------------|------------------| | 非流动资产： \n发放贷款和垫款 | | | | 债权投资 | 268,189,288.88 | 236,314,788.88 | | 其他债权投资 | | | | 长期应收款 | | | | 长期股权投资 | 44,804,297.61 | 45,466,776.18 | | 其他权益工具投资 | | | | 其他非流动金融资产 | 21,040,000.00 | 21,040,000.00 | | 投资性房地产 | 15,930,153.17 | 16,006,792.16 | | 固定资产 | 778,794,646.22 | 778,123,927.77 | | 在建工程 | 287,459,857.26 | 256,903,846.02 | | 生产性生物资产 | | | | 油气资产 | | | | 使用权资产 | 11,469,650.92 | 8,711,945.56 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 证券代码：688575 证券简称：亚辉龙 公告编号：2023-027 深圳市亚辉龙生物科技股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩暨 现金分红说明会的公告 深圳市亚辉龙生物科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 29 日发布公司 2022 年度报告及 2023 年第一季度报告，为便于广大投资者更 全面深入地了解公司 2022 年度及 2023 年第一季度经营成果、财务状况，公司计 划于 2023 年 05 月 16 日上午 11:00-12:00 举行 2022 年度暨 2023 年第一季度业 绩暨现金分红说明会，就投资者关心的问题进行交流。 一、说明会类型 http://roadshow.sseinfo.com/） 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度及 2023 年第 一季度的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息 会议召开方式：上证路演中心网络互动 会议 ...